Newsletter

Subscribe and receive updates on this company

Text STOCKS to 72727 for mobile alerts

We are excited to present Protagonist Therapeutics, Inc. (NASDAQ: PTGX).

Full DD Report for PTGX

You must become a subscriber to view this report.


Recent News from (NASDAQ: PTGX)

Protagonist Therapeutics Announces Two Oral Presentations Accepted for 23rd Congress of the European Hematology Association
NEWARK, Calif. , May 17, 2018 /PRNewswire/ -- Protagonist Therapeutics, Inc. (Nasdaq: PTGX) today announced that clinical and preclinical abstracts for PTG-300, the Company's injectable hepcidin mimetic in development for treatment of anemia and iron overload in rare blood disorders,...
Source: PR Newswire
Date: May, 17 2018 10:14
Protagonist Therapeutics Appoints Bryan Giraudo to Board of Directors
NEWARK, Calif. , May 16, 2018 /PRNewswire/ -- Protagonist Therapeutics, Inc. (Nasdaq: PTGX) today announced the appointment of Bryan Giraudo to its Board of Directors. Mr. Giraudo currently serves as Chief Financial Officer of Gossamer Bio and was previously Senior Managing Dire...
Source: PR Newswire
Date: May, 16 2018 08:00
Midday Gainers / Losers (05/10/2018)
Gainers: ARMO +67% . HEAR +63% . KOSS +34% . VTVT +24% . DEPO +22% . PBH +22% . MRAM +20% . SLDB +18% . MCEP +18% . NCTY +18% . More news on: ARMO BioSciences, Inc., Turtle Beach Corporation, Koss Corporation, Stocks on the move, , Read more ...
Source: SeekingAlpha
Date: May, 10 2018 12:45
Protagonist misses by $0.07, beats on revenue
Protagonist (NASDAQ: PTGX ): Q1 EPS of -$0.36 misses by $0.07 . Revenue of $10.8M beats by $0.9M . Press Release More news on: Protagonist Therapeutics, Earnings news and commentary, Healthcare stocks news, ,
Source: SeekingAlpha
Date: May, 09 2018 16:47
Protagonist Therapeutics Reports First Quarter 2018 Financial Results
NEWARK, Calif. , May 9, 2018 /PRNewswire/ -- Protagonist Therapeutics, Inc. (Nasdaq: PTGX) today reported its financial results for the first quarter ended March 31, 2018 . "Protagonist is continuing to build a broad and diverse pipeline of potentially transformative drug candid...
Source: PR Newswire
Date: May, 09 2018 16:02
Protagonist Therapeutics Announces Oral Presentation Accepted for Digestive Diseases Week Conference
NEWARK, Calif. , May 3, 2018 /PRNewswire/ -- Protagonist Therapeutics, Inc. (Nasdaq: PTGX) today announced that preclinical research findings on the Company's selective dual mu/delta opioid receptor agonists have been accepted for oral presentation on Saturday, June 2, 2018...
Source: PR Newswire
Date: May, 03 2018 08:00
3 Things In Biotech, March 29: Bristol And Protagonist Opposite Day In The Colon
Note: Subscribers to Avisol Capital Partners Total Pharma Tracker got an early look at this publication. Welcome to another edition of "3 Things In Biotech You Should Learn Today," a daily digest dedicated to helping you keep pace with the fast-moving world of pharmaceutical and biotec...
Source: SeekingAlpha
Date: March, 30 2018 08:00
Recent Analysis Shows ICU Medical, Motorcar Parts of America, Protagonist Therapeutics, A. Schulman, PennantPark Investment, and H&E Equipment Services Market Influences - Renewed Outlook, Key Drivers of Growth
NEW YORK, March 28, 2018 (GLOBE NEWSWIRE) -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of ICU Medical, Inc. (NASDAQ:ICUI), Motorcar Parts of America, Inc. (NASDAQ...
Source: GlobeNewswire
Date: March, 28 2018 08:25
Protagonist Therapeutics: Any Hope After Monday's Debacle?
We can easily forgive a child who is afraid of the dark; the real tragedy of life is when men are afraid of the light .” ― Plato Today we look at a small ‘ Tier 4 ’ biotech concern that imploded last week after a disappointing trial development. I don’t ...
Source: SeekingAlpha
Date: March, 28 2018 08:01
Your Daily Pharma Scoop: Flex Pharma Data, Protagonist Setback, ImmunoGen Results
A nalysis focus: Flex Pharma Flex Pharma (NASDAQ:FLKS) shares moved up sharply in early trading on Monday after the company announced positive top-line data from the phase 2 study of FLKS-787 in multiple sclerosis (MS) patients with frequent muscle cramps/spasms and spasticity. ...
Source: SeekingAlpha
Date: March, 27 2018 08:00

 


Last 5 Days Trading Activity

DateOpen PriceClose PriceHighLowVolume
2018-05-186.096.006.145.92278,017
2018-05-176.385.996.515.87260,226
2018-05-166.456.456.5256.33201,765
2018-05-156.436.456.616.34281,808
2018-05-146.556.426.785.501,529,431

Last 5 Days Short Activity

DateShort VolumeTotal VolumeShort PercentageShort Indicator
2018-05-2117,53159,49029.4688Cover
2018-05-1837,27167,89354.8967Short
2018-05-1740,10158,91568.0659Short
2018-05-1624,05340,32059.6553Short
2018-05-1549,27487,35556.4066Short

* Short Mode

Short Analysis provided by Squeeze Report. Get a complete short report on PTGX.


About Protagonist Therapeutics, Inc. (NASDAQ: PTGX)

Logo for Protagonist Therapeutics, Inc. (NASDAQ: PTGX)

Not available

 

Contact Information

 

 

Current Share Structure

  • Market Cap: $137,807,651 - 05/11/2018
  • Issue and Outstanding: 21,103,775 - 02/28/2018

 


Recent Filings from (NASDAQ: PTGX)

Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: May, 16 2018
Additional proxy soliciting materials - definitive
Filing Type: DEFA14AFiling Source: edgar
Filing Date: May, 16 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: May, 09 2018
Quarterly report with a continuing view of a company's financial position
Filing Type: 10-QFiling Source: edgar
Filing Date: May, 09 2018
Official notification to shareholders of matters to be brought to a vote (Proxy)
Filing Type: DEF 14AFiling Source: edgar
Filing Date: April, 18 2018
Additional proxy soliciting materials - definitive
Filing Type: DEFA14AFiling Source: edgar
Filing Date: April, 18 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: March, 26 2018
Amendment to a previously filed Form 4
Filing Type: 4/AFiling Source: edgar
Filing Date: March, 15 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: March, 07 2018
Annual report with a comprehensive overview of the company
Filing Type: 10-KFiling Source: edgar
Filing Date: March, 07 2018

 

 


Daily Technical Chart for (NASDAQ: PTGX)

Daily Technical Chart for (NASDAQ: PTGX)


Stay tuned for daily updates and more on (NASDAQ: PTGX)

It most certainly could but even more important is the recent overwhelming interest in the company. Check out Investors Hub and search on Twitter

More to come on (NASDAQ: PTGX)

Do your DD and if you choose, be ready to go!


 

The Research: All source information contained in this email is from the public sources mentioned below.

 

 
 

Thank you

The Subway Trader
@TheSubwayTrader

 

 


Disclaimer: The Subway Trader publishes reports providing information on selected companies. The Subway Trader is not a registered investment advisor or broker-dealer. This report is provided as an information service only, and the statements and opinions in this report should not be construed as an offer or solicitation to buy or sell any security. The Subway Trader accepts no liability for any loss arising from an investors reliance on or use of this report. An investment in PTGX is considered to be highly speculative and should not be considered unless a person can afford a complete loss of investment. The Subway Trader has received up to $100,000 worth of crypto currency from a non-affiliated third party for the publication and circulation of this report. The Subway Trader does not own any shares of PTGX and does not buy, sell, or trade any shares of PTGX. This report contains forward-looking statements, which involve risks, and uncertainties that may cause actual results to differ materially from those set forth in the forward-looking statements. Copyright 2018 by The Subway Trader. All rights reserved. Our Full Disclaimer: http://thesubwaytrader.com/disclaimer/